Small-cap biotech intelligence
Daily commentary on FDA decisions, trial readouts, financings and the stocks reacting to them — plus live market, filings and news trackers.
The Briefing
Market Pulse
CSE and TSX-V junior mining opened with constructive momentum on July 30 as gold held above $4,080 USD/oz and silver stabilized near $58 USD/oz; catal…
News Wire
Filings Watch
Crescent Biopharma (CBIO) closed a public offering on July 16, 2026, raising $143.7 million in gross proceeds before underwriting discounts, commissions, and other offering expenses, according to the…
Apnimed is moving to raise $150 million on Nasdaq this week — ticker APMD — with a February 28, 2027 FDA decision date on its oral obstructive sleep apnea drug already on the calendar.
Discovery drill hole 3TS-26-39 intersected 9.10 metres grading 14.70 grams per tonne gold and 36.70 g/t silver, with an estimated true width of 7.00 metres, according to Independence Gold Corp.'s…
Twenty years of failed attempts at the PI3K/AKT/mTOR pathway ended on July 14, 2026, when the FDA approved Celcuity Inc.'s (Nasdaq: CELC) Revtorpyk (gedatolisib) for HR+/HER2− locally advanced or…
The FDA granted accelerated approval to Vera Therapeutics' TRUTAKNA (atacicept-vymj) on July 7, 2026. The number that defined the filing: a 46% reduction from baseline in proteinuria, drawn from a…
Crystalys Therapeutics announced on July 22, 2026 a $130 million Series B financing — oversubscribed and closed — less than a year after the company launched with a $205 million Series A announced…
Oncolytics Biotech Inc. (Nasdaq: ONCY) received its third FDA Fast Track designation for pelareorep on July 20, 2026 — this one for pelareorep combined with a checkpoint inhibitor in patients with…
Dyne Therapeutics landed a concrete regulatory milestone on July 20, 2026: the FDA accepted its Biologics License Application for zeleciment rostudirsen — also designated DYNE-251, or z-rostudirsen —…
The FDA accepted Dyne Therapeutics' Biologics License Application for zeleciment rostudirsen on July 20, 2026, assigning a PDUFA target action date of January 21, 2027 — a hard deadline that now…
Nuvation Bio reported updated Phase 2 data for safusidenib in IDH1-mutant glioma, with a 51.9% response rate and a 79.1% three-year progression-free rate.
REGENXBIO reported long-term data showing its AbbVie-partnered gene therapy sura-vec preserved vision and cut injection burden through five years in wet AMD.
4DMT presented two-year Phase 2b PRISM data showing its gene therapy 4D-150 cut anti-VEGF treatment burden by 78% while maintaining vision in wet AMD.
One concise briefing. The movers, the filings, the FDA calendar.